---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-017058"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:48:39.915115+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY

## Summary
- Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.
- ADHD Portfolio net revenue up 49% to $12.3M; Rx gross margin improved to 74%.
- Consumer Health net revenue down 56% to $4.0M; wind-down continues as planned.
- TTM companywide adjusted EBITDA positive $15.4M; Rx Business TTM adjusted EBITDA $17.1M.
- Cash $19.8M; manufacturing transition expected to improve margins.

## SEC filing metadata
- accession: 0001437749-24-017058
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/0001437749-24-017058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/aytu20240223_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-017058
- JSON: https://secwatch.observer/filing/0001437749-24-017058.json
- Plain text: https://secwatch.observer/filing/0001437749-24-017058.txt

## Key facts
- Earnings Releases
  AYTU BIOPHARMA, INC reported fiscal 2024 third quarter results: revenue $18.0 million, net income $2.9 million, EPS $0.52 per share.
  - Period: fiscal 2024 third quarter
  - Revenue: $18.0 million
  - Net income: $2.9 million
  - EPS: $0.52 per share
  - Result: reported results
  source text: on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter. ​ Q3 2024 Highlights ● Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment. ● ADHD Portfolio (Adzenys XR-ODT® and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/0001437749-24-017058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.